ArticlemBio2018
Inhibition of EGFR Signaling Protects from Mucormycosis.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 69 citations in OpenAlex.
- Emerging host-directed strategies for overcoming drug resistance and immune evasion in Staphylococcus aureus infections.Journal of advanced research · 2026Review
- Article
- Transcriptomic and proteomic profiling of pulmonary mucormycosis reveals a failed activation of host immune response.Frontiers in immunology · 2026Article
- Exploring the therapeutic potential of Thymus vulgaris ethanol extract: a computational screening for antimicrobial compounds against COVID-19 induced mucormycosis.Scientific reports · 2025Article
- Cutaneous mucormycosis in systemic lupus erythematosus: a case report.Frontiers in immunology · 2025Article
- A human-relevant alternative infection model for mucormycosis using the silkworm Bombyx mori.PloS one · 2025Article
- Article
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Epidermal Growth Factor Receptor Signaling Governs the Host Inflammatory Response to Invasive Aspergillosis.bioRxiv : the preprint server for biology · 2024Article
- Multiple roles for hypoxia inducible factor 1-alpha in airway epithelial cells during mucormycosis.Nature communications · 2024Article
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Molecular mechanisms that govern infection and antifungal resistance in Mucorales.Microbiology and molecular biology reviews : MMBR · 2024Review
- Experimental Models to Study the Pathogenesis and Treatment of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Immune responses to human fungal pathogens and therapeutic prospects.Nature reviews. Immunology · 2023Review
- Article
- Mucormycosis in 2023: an update on pathogenesis and management.Frontiers in cellular and infection microbiology · 2023Review
- Human Airway Epithelium Responses to Invasive Fungal Infections: A Critical Partner in Innate Immunity.Journal of fungi (Basel, Switzerland) · 2022Review
- Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.Journal of clinical medicine · 2022Review
- Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.Journal of infection and public health · 2022Review
- IFN-γ Mediated Signaling Improves Fungal Clearance in Experimental Pulmonary Mucormycosis.Mycopathologia · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Tonya N WatkinsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Teclegiorgis GebremariamDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Marc SwidergallDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Amol C ShettyInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Karen T GrafInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Abdullah AlqarihiDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Sondus AlkhazrajiDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Abrar I AlsaadiDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Vonetta L EdwardsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Scott G FillerDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Ashraf S IbrahimDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor, UCLA Medical Center, Torrance, California, USA.
Vincent M BrunoInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA vbruno@som.umaryland.edu.
University of Maryland, Baltimore · USHarbor–UCLA Medical Center · USUCLA Medical Center · USThe Lundquist Institute · US
Funding
Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI RASKO, DAVID A · 2014 to 2023
$36.5MEXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9MNovel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3MC. albicans invasion and proliferation during oral infectionR01DE026600 · NIDCR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI FILLER, SCOTT G, MITCHELL, AARON P · 2017 to 2021
$3.0MEndothelial invasion by yeast-phase CandidaR01AI124566 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI FILLER, SCOTT G, MITCHELL, AARON P · 2016 to 2020
$2.7MNovel Candida albicans host receptors during infection and immune responseK99DE026856 · NIDCR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SWIDERGALL, MARC · 2017 to 2018
$267kNIAID NIH HHS R01 AI063503NIAID NIH HHS R01 AI124566NIAID NIH HHS U19 AI110820NIDCR NIH HHS K99 DE026856NIDCR NIH HHS R01 DE026600NIGMS NIH HHS R25 GM055036
Abstract
Mucormycosis is a life-threatening, invasive fungal infection that is caused by various species belonging to the order Mucorales.
Indexed as
Host-Pathogen InteractionsA549 CellsAnimalsCetuximabDisease Models, AnimalErbB ReceptorsGefitinibGene Regulatory NetworksHumansLungMaleMiceMice, Inbred ICRMucormycosisPhosphorylationProtein Kinase InhibitorsCetuximabEGFR protein, humanEGFR protein, mouseErbB ReceptorsGefitinibProtein Kinase InhibitorsEGFRgefitinibmucormycosisRhizopus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.